Abstract
Didanosine (ddI) is currently used in the management of patients infected by the human immunodeficiency virus. Rifabutin (RBT) is being extensively used for prophylaxis against Mycobacterium avium complex (MAC) infections. Due to its acid-labile characteristics, ddI must be administered with a buffer. Recent reports have indicated that absorption of ketoconazole, ciprofloxacin, and dapsone, etc., in the gut is altered by concomitant ddI dosing. We have assessed whether concomitant dosing of ddI as antiretroviral therapy modifies RBT absorption in the gut, its steady-state pharmacokinetics, and/or safety in 15 patients with AIDS. Of the 15 patients enrolled, 12 completed the study and 3 receiving 600 mg of RBT with concomitant ddI administration withdrew prematurely from the study. Steady-state RBT pharmacokinetics were assessed on day 13 (ddI plus RBT) and day 16 (RBT alone). The ddI doses (adjusted for body weight) were 167 to 375 mg twice daily, while RBT was administered as a single 300- or 600-mg daily dose. No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h). The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar. Assessment based on urinary recovery of RBT (3.1 versus 3.7 mg) and its predominant deacetyl metabolite, LM565 (1.6 versus 1.4 mg), showed no apparent effect of ddI. The fraction of the RBT dose converted to LM565, as suggested by the ratio of AUC of the metabolite to AUC of the parent drug, was also unaltered (0.15 versus 0.12). A ratio analysis (day 13/day 16) of the RBT pharmacokinetic estimates showed that the 95% confidence intervals for all parameters were inclusive of one. Furthermore, the brief interruption of ddI therapy over this short study period at steady state produced no clinically significant changes in body weight, hematology, and renal and pancreatic functions. Therefore, concomitant administration of ddI appears not to affect RBT absorption in the gut and its disposition or safety in patients with AIDS.
Full Text
The Full Text of this article is available as a PDF (159.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barry M., Howe J. L., Ormesher S., Back D. J., Breckenridge A. M., Bergin C., Mulcahy F., Beeching N., Nye F. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br J Clin Pharmacol. 1994 May;37(5):421–426. doi: 10.1111/j.1365-2125.1994.tb05708.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Battaglia R., Pianezzola E., Salgarollo G., Zini G., Strolin Benedetti M. Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man. J Antimicrob Chemother. 1990 Dec;26(6):813–822. doi: 10.1093/jac/26.6.813. [DOI] [PubMed] [Google Scholar]
- Dolin R., Lambert J. S., Morse G. D., Reichman R. C., Plank C. S., Reid J., Knupp C., McLaren C., Pettinelli C. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 5):S540–S551. [PubMed] [Google Scholar]
- Hartman N. R., Yarchoan R., Pluda J. M., Thomas R. V., Marczyk K. S., Broder S., Johns D. G. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990 May;47(5):647–654. doi: 10.1038/clpt.1990.86. [DOI] [PubMed] [Google Scholar]
- Knupp C. A., Graziano F. M., Dixon R. M., Barbhaiya R. H. Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob Agents Chemother. 1992 Oct;36(10):2075–2079. doi: 10.1128/aac.36.10.2075. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lewis R. C., Hatfield N. Z., Narang P. K. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharm Res. 1991 Nov;8(11):1434–1440. doi: 10.1023/a:1015865526655. [DOI] [PubMed] [Google Scholar]
- May D. B., Drew R. H., Yedinak K. C., Bartlett J. A. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy. 1994 Sep-Oct;14(5):509–513. [PubMed] [Google Scholar]
- Nightingale S. D., Cameron D. W., Gordin F. M., Sullam P. M., Cohn D. L., Chaisson R. E., Eron L. J., Sparti P. D., Bihari B., Kaufman D. L. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. 1993 Sep 16;329(12):828–833. doi: 10.1056/NEJM199309163291202. [DOI] [PubMed] [Google Scholar]
- Sahai J., Gallicano K., Oliveras L., Khaliq S., Hawley-Foss N., Garber G. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther. 1993 Mar;53(3):292–297. doi: 10.1038/clpt.1993.24. [DOI] [PubMed] [Google Scholar]
- Skinner M. H., Hsieh M., Torseth J., Pauloin D., Bhatia G., Harkonen S., Merigan T. C., Blaschke T. F. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother. 1989 Aug;33(8):1237–1241. doi: 10.1128/aac.33.8.1237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Strolin Benedetti M., Efthymiopoulos C., Sassella D., Moro E., Repetto M. Autoinduction of rifabutin metabolism in man. Xenobiotica. 1990 Nov;20(11):1113–1119. doi: 10.3109/00498259009046832. [DOI] [PubMed] [Google Scholar]
- Vella S. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 (Suppl 1):S58–S61. [PubMed] [Google Scholar]